The Netherlands Drug Situation 2010 - Trimbos-instituut

addiction care centre (hepatitis B infection in 49% of drug users in treatment and hepatitisC infection in 61%; see also above) (Schreuder et al., submitted).Table 6.1.3: Markers for hepatitis B and C infections in 229 detainees in the South ofthe NetherlandsAll detaineesEver hard drugusing detaineesEver drug injectingdetaineesAnti HBc 19 14 8Anti HBsAg 3 3 1Anti HCV 17 15 11HCV RNA 11 10 6Source: RIVM (Schreuder and Van Veen 2010)Table 6.1.4:Previous diagnosis of hepatitis B or C in detainees with positive test result(self report data)Positive testsEver being diagnosedAnti HBc 19 3 (16%)Anti HBsAg 3 0Anti HCV 17 9 (53%)HCV-RNA 11 5 (45%)Source: RIVM (Schreuder and Van Veen 2010)The hepatitis C prevalence data from this prison study are in accordance with anotherrecent Dutch study estimating the hepatitis C prevalence in prison (Leemrijse et al.,2010). This study searched the medical files of a sample of 3360 detainees drawn from11 (of a total of 56) penitentiary institutions. The sample comprised 8% women and themean age for both genders was 35 years. For 814 detainees a test result for antibodies against HCV was present in the medicalfile, of whom 82 were positive (10%). HCV-RNA results (indicating an active infection)were available for 24 persons and 18 (75%) were positive. As the medical filesare incomplete, it was not possible to make an exact estimation of the yearly HCVprevalence. Instead, the prevalence of hepatitis C infection in the sample was roughlyestimated, somewhere between 2.0% and 10.7%. For most risk factors, details were lacking in the patient files. Nevertheless, injectingdrug use was identified as a significant risk factor (p